NONPARALLEL EFFECTS OF RENIN INHIBITOR TREATMENT ON PLASMA-RENIN ACTIVITY AND ANGIOTENSIN-I AND ANGIOTENSIN-II IN HYPERTENSIVE SUBJECTS - AN ASSAY-RELATED ARTIFACT

被引：39

作者：

DERKX, FHM ^{[1
]}

VANDENMEIRACKER, AH ^{[1
]}

FISCHLI, W ^{[1
]}

ADMIRAAL, PJJ ^{[1
]}

VELD, AJMI ^{[1
]}

VANBRUMMELEN, P ^{[1
]}

SCHALEKAMP, MADH ^{[1
]}

机构：

[1] ERASMUS UNIV,DEPT INTERNAL MED 1,ROOM H 362,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1991年 / 4卷 / 07期

关键词：

ANGIOTENSINS; ANTIHYPERTENSIVE DRUGS; PLASMA RENIN ACTIVITY; RENIN; RENIN INHIBITORS; PROTEIN BINDING;

D O I：

10.1093/ajh/4.7.602

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Nonparallel effects of renin inhibitor treatment on plasma renin activity (PRA) and the plasma levels of angiotensins (ANG), as well as on blood pressure, have been observed in subjects with hypertension. This study addresses the possibility that renin inhibitors may show a high degree of plasma protein binding in vivo and that displacement of protein-bound inhibitor during the assay of PRA in vitro may lead to overestimation of renin inhibition. Indeed, with the ultrafiltration technique it was found that 96% of the novel renin inhibitor Ro 42-5892, when added to EDTA plasma, was bound to protein. The angiotensinase inhibitors phenylmethylsulfonyl fluoride (PMSF) and 8-hydroxyquinoline sulfate (8-OHQ), which are currently used in PRA assays, caused a displacement of protein-bound inhibitor, thereby increasing its free concentration. This displacement was sufficient to explain the reduction in IC 50 of Ro 42-5892, which was seen in the PRA assay when PMSF and 8-OHQ were added to plasma. Such reductions in IC 50 were also seen with the renin inhibitors CGP 29-287, CGP 38-560A, and SR 43-845. When Ro 42-5892 was given, 1 mg/kg intravenously in 10 min, to subjects with hypertension, it appeared that plasma ANG I and II returned to baseline after 6-8 h, whereas PRA measured in the presence of PMSF and 8-OHQ was still suppressed. However, when PRA was measured without these angiotensinase inhibitors, the inhibition of PRA was parallel to the suppression of ANG I and II. Thus, one must be cautious when using PRA to monitor the in vivo effects of renin inhibitors on the renin-angiotensin system, since the very method of PRA measurement may mislead the observer into overestimating the magnitude of drug effect.

引用

页码：602 / 609

页数：8

共 27 条

[1] Webb D.J., Manhem P., Ball S.G., Et al., A study of the renin inhibitor H142 in man, J Hypertens, 3, pp. 653-658, (1985)
[2] De Gasparo M., Cumin F., Nussberger J., Et al., Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers, Br J Clin Pharmacol, 27, pp. 587-596, (1989)
[3] Delabays A., Nussberger J., Porchet M., Et al., Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans, Hypertension, 13, pp. 948-953, (1989)
[4] Nussberger D.A., De Gasparo M., Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers, Hypertension, 13, pp. 948-953, (1989)
[5] Jeunemaitre X., Menard J., Nussberger J., Et al., Plasma angiotensins, renin and blood pressure during acuterenin inhibition by CGP 38560A in hypertensive patients, Am J Hypertens, 2, pp. 819-827, (1989)
[6] Bursztyn M., Gavras I., Tifft C.P., Et al., Effects of a novel renin inhibitor in patients with essential hypertension, JCardiovasc Pharmacol, 15, pp. 493-500, (1990)
[7] Haber E., Koerner T., Page L.B., Et al., Application. Of a radioimmunoassay for angiotensin I to the physiologicalmeasurements of plasma renin activity in normal humansubjects, J Clin Endocrinol, 29, pp. 1349-1355, (1969)
[8] Oparil S., Koerner T.J., Haber E., Effects of pH and enzyme inhibitors on apparent generation of angiotensin I and II, J Clin Endocrinol Metab, 39, pp. 965-968, (1974)
[9] Sealey J.E., Campbell G.A., Preibisz J.J., Hormone assays: Renin, aldosterone, peripheral vein, renal vein and urinary assays. Guidelines to methodology and interpretation, Hypertension:Pathophysiology, Diagnosis, and Management, pp. 1443-1460, (1990)
[10] Meiracker A.H., Admiraal P., Man Int Veld A.J., Prolonged blood pressure reduction by a novel orallyactive renin inhibitor Ro 42-5892 in essential hypertension, Br Med J, 301, pp. 205-210, (1990)

← 1 2 3 →